GlassScriptPhysician profile
Roopesh Kumar Kantala
NPI 1811922198
$490,635.64
in general payments reported to CMS, 2019-2025
71 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $25K · 2021: $60K · 2022: $123K · 2023: $78K · 2024: $42K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Consulting Fee: $34K · Travel and Lodging: $16K · Food and Beverage: $13K · Honoraria: $4,945 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,890.00 |
| Consulting Fee | $34,279.00 |
| Travel and Lodging | $15,955.69 |
| Food and Beverage | $12,665.74 |
| Honoraria | $4,945.00 |
| Education | $140.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $223,396.32 | 2019-2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $101,771.93 | 2019-2025 | Libtayo |
| Genzyme Corporation | $45,110.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20,405.12 | 2019-2025 | Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $19,100.90 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $11,830.72 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $11,592.53 | 2019-2025 | |
| Seagen INC. | $7,214.12 | 2019-2023 | Adcetris, Tukysa |
| Pharmacosmos Therapeutics INC. | $6,654.17 | 2022-2025 | Monoferric |
| Incyte Corporation | $5,896.57 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Karyopharm Therapeutics INC. | $5,180.12 | 2020-2025 | Xpovio |
| Celgene Corporation | $4,363.83 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Clovis Oncology, INC. | $3,860.85 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,488.23 | 2020-2025 | |
| Abbvie INC. | $2,217.08 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $1,973.81 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $1,969.09 | 2020-2024 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $1,419.79 | 2019-2025 | Carvykti, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,406.95 | 2019-2025 | |
| Taiho Oncology, INC. | $1,400.00 | 2024 | |
| Blueprint Medicines Corporation | $1,184.86 | 2020-2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $813.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $795.57 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Genentech USA, INC. | $753.65 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Pharmacyclics LLC, An Abbvie Company | $514.26 | 2019-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $509.04 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $505.58 | 2019-2023 | Vectibix, Nplate, Lumakras |
| Gilead Sciences, INC. | $494.56 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $334.54 | 2019-2025 | Vyloy, Padcev, Xospata |
| Eisai INC. | $318.24 | 2019-2025 | |
| Puma Biotechnology, INC. | $235.66 | 2019-2025 | |
| Caris Mpi, INC. | $219.82 | 2025 | Mi Cancer Seek |
| Sobi, INC | $217.26 | 2024 | |
| Kite Pharma, INC. | $196.55 | 2019-2025 | Yescarta |
| Array Biopharma INC | $191.03 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Genmab U.S., INC. | $180.41 | 2023-2025 | Epkinly, Tivdak |
| Mirati Therapeutics, INC. | $164.13 | 2023-2024 | Krazati |
| Tempus Ai, INC | $157.60 | 2024-2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $157.26 | 2019-2025 | Onivyde |
| Emd Serono, INC. | $151.09 | 2019-2025 | Tepmetko, Bavencio |
| Alexion Pharmaceuticals, INC. | $131.58 | 2023-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.39 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $117.20 | 2025 | Fyarro |
| Aurobindo Pharma USA, INC. | $113.08 | 2019 | |
| Beigene USA, INC. | $110.37 | 2022-2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $106.09 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $101.68 | 2021-2025 | Zepzelca |
| Sumitomo Pharma America, INC. | $72.40 | 2023-2024 | Orgovyx |
| Sanofi-Aventis U.S. LLC | $66.99 | 2021 | |
| Secura Bio, INC. | $65.52 | 2020 | |
| Springworks Therapeutics, INC. | $62.31 | 2024-2025 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $34.76 | 2020-2022 | |
| Dova Pharmaceuticals | $33.79 | 2021 | |
| Hologic Sales and Service, LLC | $33.51 | 2024 | Aptima |
| Tersera Therapeutics LLC | $32.22 | 2023 | Zoladex |
| Deciphera Pharmaceuticals INC. | $31.11 | 2025 | Romvimza, Qinlock |
| G1 Therapeutics, INC. | $30.17 | 2022-2023 | Cosela |
| Pharmaessentia USA Corporation | $28.13 | 2025 | Besremi |
| Stemline Therapeutics INC. | $28.04 | 2023 | Orserdu |
| Exelixis INC. | $22.48 | 2025 | Cabometyx |
| Immunomedics, INC. | $21.95 | 2020 | |
| Adc Therapeutics America, INC. | $21.75 | 2023 | |
| Coherus Oncology, INC. | $19.77 | 2025 | Loqtorzi |
| Adaptive Biotechnologies Corporation | $16.68 | 2025 | Clonoseq |
| Myovant Sciences INC. | $16.63 | 2021 | |
| Agios Pharmaceuticals, INC. | $15.26 | 2025 | Pyrukynd |
| Mylan Institutional INC. | $15.15 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.62 | 2020 | |
| Pharmaand Gmbh | $13.33 | 2025 | Rubraca |
| Lexicon Pharmaceuticals, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopesh Kantala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.